Squarepoint
MAZE

Squarepoint’s Maze Therapeutics MAZE Stock Holding History

Squarepoint’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$580K Buy
19,434
+5,822
+43% +$153K ﹤0.01% 3313
2026
Q1 		$406K Buy
+13,612
New +$601K ﹤0.01% 3471

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Squarepoint's MAZE Position: Q2 2026 in Review

Squarepoint increased its Maze Therapeutics (MAZE) stake by 43% in Q2 2026, buying an estimated $153K and bringing the position to 19,434 shares worth $580K. The position accounts for ﹤0.01% of the portfolio, ranked #3313.

Squarepoint first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Squarepoint held 19,434 shares of Maze Therapeutics worth $580K as of Q2 2026.
  • Squarepoint bought 5,822 Maze Therapeutics shares in Q2 2026, an estimated $153K.
  • Maze Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3313 holding.
  • Squarepoint first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.